Get the Stockscreener App
50.49
2.39%
1.18
Crinetics Pharmaceuticals Inc stock is traded at $50.49, with a volume of 1.11M.
It is up +2.39% in the last 24 hours and up +17.91% over the past month.
Crinetics Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its products include Paltusotine and Atumelnant.
See More
Previous Close:
$49.31
Open:
$49
24h Volume:
1.11M
Relative Volume:
0.72
Market Cap:
$4.79B
Revenue:
$4.72M
Net Income/Loss:
$-277.91M
P/E Ratio:
-13.54
EPS:
-3.73
Net Cash Flow:
$-203.56M
1W Performance:
+8.19%
1M Performance:
+17.91%
6M Performance:
+56.95%
1Y Performance:
-9.22%
1-Day Range:
$48.58
$50.98
1-Week Range:
$46.49
$50.98
52-Week Range:
$24.10
$56.53
Crinetics Pharmaceuticals Inc Stock (CRNX) Company Profile
Name
Crinetics Pharmaceuticals Inc
Sector
Industry
Phone
858-450-6464
Address
6055 LUSK BLVD., SAN DIEGO, CA
Compare CRNX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CRNX
Crinetics Pharmaceuticals Inc
|
50.49 | 4.68B | 4.72M | -277.91M | -203.56M | -3.73 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.04 | 113.14B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.29 | 78.49B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
877.94 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.55 | 54.51B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
197.01 | 41.64B | 447.02M | -1.18B | -906.14M | -6.1812 |
Crinetics Pharmaceuticals Inc Stock (CRNX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-10-25 | Initiated | Goldman | Neutral |
| Mar-25-25 | Initiated | Stifel | Buy |
| Feb-11-25 | Initiated | TD Cowen | Buy |
| Feb-04-25 | Initiated | Wolfe Research | Peer Perform |
| Jan-22-25 | Upgrade | Jefferies | Hold → Buy |
| Mar-06-24 | Initiated | Citigroup | Buy |
| Jan-16-24 | Initiated | Morgan Stanley | Overweight |
| Dec-21-23 | Initiated | Jefferies | Hold |
| Nov-20-23 | Resumed | JP Morgan | Overweight |
| Oct-24-23 | Resumed | Cantor Fitzgerald | Overweight |
| Aug-31-23 | Initiated | Oppenheimer | Outperform |
| Apr-24-23 | Initiated | Piper Sandler | Overweight |
| Mar-30-23 | Initiated | Robert W. Baird | Outperform |
| Nov-30-21 | Initiated | JMP Securities | Mkt Outperform |
| Nov-23-21 | Initiated | Evercore ISI | Outperform |
| Jun-18-21 | Upgrade | JP Morgan | Neutral → Overweight |
| Dec-23-19 | Initiated | ROTH Capital | Buy |
| Feb-14-19 | Initiated | H.C. Wainwright | Buy |
| Aug-13-18 | Initiated | JP Morgan | Neutral |
| Aug-13-18 | Initiated | Leerink Partners | Outperform |
| Aug-13-18 | Initiated | Piper Jaffray | Overweight |
View All
Crinetics Pharmaceuticals Inc Stock (CRNX) Latest News
Does Crinetics Pharmaceuticals Still Offer Value After Its Recent Share Price Rebound? - Yahoo Finance
Trading the Move, Not the Narrative: (CRNX) Edition - news.stocktradersdaily.com
Crinetics Announces First Patient Dosed in Pivotal Adult Trial of Atumelnant in Congenital Adrenal Hyperplasia (CAH) - The Manila Times
Crinetics Pharmaceuticals Doses First Patient in Phase 3 Trial of Atumelnant for Classic Congenital Adrenal Hyperplasia - Quiver Quantitative
Crinetics Announces First Patient Dosed in Pivotal Adult Trial of Atumelnant in Congenital ... - Enidnews.com
Crinetics Pharmaceuticals (CRNX) poised for transformational growth in 2026: Piper Sandler - MSN
Crinetics Pharmaceuticals (CRNX) Poised for Transformational Growth in 2026: Piper Sandler - Yahoo Finance
Crinetics Pharmaceuticals, Inc. (CRNX) Poised for Transformational Growth in 2026: Piper Sandler - Insider Monkey
Crinetics Pharmaceuticals Announces December 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
JPMorgan Chase & Co. Has $9.55 Million Stock Holdings in Crinetics Pharmaceuticals, Inc. $CRNX - MarketBeat
Did First-in-Human BRAVESST2 Trial of CRN09682 Just Shift Crinetics Pharmaceuticals' (CRNX) Investment Narrative? - Sahm
Crinetics Pharmaceuticals, Inc. $CRNX Stock Holdings Increased by Walleye Capital LLC - MarketBeat
Schroder Investment Management Group Purchases 63,517 Shares of Crinetics Pharmaceuticals, Inc. $CRNX - MarketBeat
How Crinetics Pharmaceuticals Inc. (6Z4) stock moves in volatile trading sessionsMarket Sentiment Summary & Daily Profit Focused Screening - Newser
Can Crinetics Pharmaceuticals Inc. (6Z4) stock surprise markets with earningsEntry Point & Advanced Technical Signal Analysis - Newser
CRNX SEC FilingsCrinetics Pharmaceuticals 10-K, 10-Q, 8-K Forms - Stock Titan
Why Crinetics Pharmaceuticals Inc. stock could outperform in 2025July 2025 Opening Moves & Entry and Exit Point Strategies - Newser
Is Crinetics Pharmaceuticals Inc. stock gaining market share2025 Performance Recap & Reliable Intraday Trade Plans - Newser
Decheng Capital LLC Cuts Stake in Crinetics Pharmaceuticals, Inc. $CRNX - MarketBeat
How strong dollar benefits Crinetics Pharmaceuticals Inc. (6Z4) stockStock Surge & Weekly High Return Stock Opportunities - Newser
Why Crinetics Pharmaceuticals Inc. (6Z4) stock stays resilient2025 Year in Review & Real-Time Volume Analysis Alerts - Newser
Crinetics doses first patient in phase 1/2 trial of novel cancer drug By Investing.com - Investing.com South Africa
Crinetics Pharmaceuticals Executive Sells 5,000 Shares - TradingView
Carcinoid Syndrome Market to Expand Significantly by 2034, - openPR.com
Crinetics Pharmaceuticals (CRNX): Reassessing Valuation After a 3-Month Rebound and DCF Upside Signal - Yahoo Finance
Assessing Crinetics Pharmaceuticals Valuation After Stock Volatility and Pipeline Progress in 2025 - Sahm
Crinetics Pharmaceuticals Says First Patient Dosed in Phase 1/2 Neuroendocrine Tumors Study - MarketScreener
Crinetics Announces First Patient Dosed in Phase 1/2 Trial Evaluating CRN09682 for the Treatment of Neuroendocrine Tumors and Other Somatostatin Receptor 2-Expressing Tumors - Koreabizwire
Crinetics announces first patient dosed in phase 1/2 trial evaluating CRN09682 - MarketScreener
Crinetics Pharmaceuticals doses first patient in novel tumor treatment trial - Traders Union
Crinetics doses first patient in phase 1/2 trial of novel cancer drug - Investing.com Australia
Crinetics (CRNX) Advances CRN09682 in Clinical Trials for Neuroe - GuruFocus
Crinetics (Nasdaq: CRNX) starts Phase 1/2 BRAVESST2 trial of CRN09682 NDC therapy - Stock Titan
Fisher Asset Management LLC Cuts Holdings in Crinetics Pharmaceuticals, Inc. $CRNX - MarketBeat
Is Crinetics Pharmaceuticals Inc. (6Z4) stock prepared for digital transitionQuarterly Risk Review & Free Weekly Watchlist of Top Performers - Newser
XTX Topco Ltd Acquires Shares of 34,013 Crinetics Pharmaceuticals, Inc. $CRNX - MarketBeat
Prudential Financial Inc. Has $4.69 Million Position in Crinetics Pharmaceuticals, Inc. $CRNX - MarketBeat
Crinetics Pharmaceuticals, Inc. $CRNX Shares Purchased by American Century Companies Inc. - MarketBeat
(CRNX) Volatility Zones as Tactical Triggers - news.stocktradersdaily.com
Officer Pizzuti Files To Sell 5,000 Of Crinetics Pharmaceuticals Inc [CRNX] - TradingView
Crinetics Pharmaceuticals (CRNX): Evaluating Valuation After Pivotal Phase 3 Milestone for Paltusotine in Carcinoid Syndrome - Sahm
Will Crinetics Pharmaceuticals Inc. stock benefit from green energy trends - moha.gov.vn
Franklin Resources Inc. Sells 314,143 Shares of Crinetics Pharmaceuticals, Inc. $CRNX - MarketBeat
Biotech Fund Dumps $12.3 Million in Crinetics Stock as Shares Remain 19% Lower on the Year - AOL.com
Crinetics Pharmaceuticals Inc, Inst Holders, 2Q 2019 (CRNX) - 富途牛牛
AXQ Capital LP Acquires New Shares in Crinetics Pharmaceuticals, Inc. $CRNX - MarketBeat
Segall Bryant & Hamill LLC Buys 30,243 Shares of Crinetics Pharmaceuticals, Inc. $CRNX - MarketBeat
Crinetics Pharmaceuticals (CRNX) Stock Analysis Report | Ratings, Financials & Performance - Benzinga
Geode Capital Management LLC Raises Stake in Crinetics Pharmaceuticals, Inc. $CRNX - MarketBeat
Crinetics Pharmaceuticals (CRNX): Valuation in Focus After Key Phase 3 Paltusotine Trial Milestone - Sahm
What technical signals suggest for Crinetics Pharmaceuticals Inc. stockTake Profit & Risk Controlled Stock Pick Alerts - newser.com
Crinetics Pharmaceuticals Inc Stock (CRNX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Crinetics Pharmaceuticals Inc Stock (CRNX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Pizzuti Dana | Chief Med and Dev Officer |
Dec 01 '25 |
Sale |
45.02 |
5,000 |
225,100 |
66,837 |
1.08%
0.91%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):